Factor VIII gene therapy - Corautus Genetics

Drug Profile

Factor VIII gene therapy - Corautus Genetics

Alternative Names: Factor VIII MAXIMUM-AD; MAX-AD Factor VIII gene therapy

Latest Information Update: 09 Apr 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter Healthcare Corporation; Corautus Genetics
  • Class Blood coagulation factors; Coagulants
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haemophilia A

Most Recent Events

  • 20 Feb 2003 GenStar Therapeutics Corporation has merged with Vascular Genetics to form Corautus Genetics
  • 17 Feb 2003 Discontinued - Phase-I for Haemophilia A in USA (Parenteral)
  • 18 Jun 2002 Further preclinical results have been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top